Jasper Therapeutics Overview
Get informed when a big investor buys or sells
+ Follow-2165.39%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Jasper Therapeutics (JSPR) currently reports a ROE of -2165.39%. That is below the sector sector average of 11.67%. Use the charts on this page to explore Jasper Therapeutics's ROE history and peer comparisons.
Jasper Therapeutics's ROE of -2165.39% is lower than the its sector sector average of 11.67%. That is roughly 18661.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Jasper Therapeutics's current -2165.39% should be judged against industry norms (sector average: 11.67%) and against JSPR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -2165.39%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.67%. From there, open related valuation or income-statement pages for Jasper Therapeutics, and consider following JSPR for alerts when major investors trade the stock.
